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Abstract 
Background: Poor adherence to medications is a significant problem that leads to increased 
morbidity, mortality, and health care costs. Recommended approaches to address medication 
adherence vary, and existing practice guidelines are unclear. 
Purpose: This review evaluated clinical practice guidelines designed to help health care 
providers address patients‟ medication adherence. 
Methods: Multiple search methods were used to identify national or international guidelines 
addressing medication adherence. We included guidelines published in English, as well as 
guidelines with an English-language summary or translation. 
Results: We identified 23 guidelines of varying detail and quality. Recommendations were 
categorized as assessment strategies (n=20 guidelines); educational strategies (n=18); 
behavioral strategies (n=17); therapeutic relationship, communication, and provider factors 
(n=19); and addressing outside influences/co-morbidities (n=10).  
Conclusions: Future guidelines should be more clearly guided by research findings and 
comparative effectiveness methods. When implemented, guidelines will facilitate health care 
providers and health systems in supporting optimal adherence and improved health outcomes.  
 
Keywords: medication adherence, guidelines, systematic review, evidence-based practice  
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Systematic Review of Clinical Practice Guidelines for the Improvement of Medication Adherence 
 
Introduction 
 Adherence to medications is defined as the process by which patients take their 
medications as prescribed and is composed of three parts: initiation (obtaining the medication 
and taking the first dose), implementation (taking each prescribed dose in a timely manner), and 
discontinuation (ceasing to take the medication) [1]. This definition assumes that the prescribing 
is appropriate and that the patient and provider agree on the treatment plan. This agreement on 
the treatment plan, often called concordance, is considered to be a separate, but related, 
concept from adherence. It is essential for medications to be used effectively and for patients to 
achieve the clinical benefit from medication therapy. 
 The World Health Organization, in a 2003 report, declared non-adherence to medical 
treatment a major public health concern, particularly among patients with chronic conditions [2], 
with about half of patients estimated to be non-adherent [3]. Suboptimal adherence to 
prescribed medication regimens exists with all clinical conditions and populations, leading to 
poorer treatment outcomes [4], inappropriate dose escalation [5], increased risk for adverse 
health events, misdiagnosis, and higher utilization of health care services, hospitalizations, and 
health care costs [6, 5]. Estimates of the annual total (direct and indirect) cost of non-adherence 
range as high as $300 billion USD [7]. The high prevalence and detrimental impact on clinical 
and economic outcomes point toward a need for guidance on assessment of medication non-
adherence, as well as strategies to overcome it. 
 Clinical practice guidelines are defined by the U.S. Institute of Medicine as “statements 
that include recommendations intended to optimize patient care” [8]. Clinical practice guidelines 
should have a clear scope and purpose, and should ideally include all stakeholders in the 
guideline development process [8, 9]. Guidelines should be developed from a systematic review 
of existing knowledge using a transparent process that avoids or minimizes conflicts of interest 
and bias [9, 8]. When appropriate, clinical practice guidelines development should involve 
patient and caregiver groups, and potentially have versions developed directed at caregivers [8, 
10]. It is currently unclear which guidelines include recommendations for how clinicians should 
address medication non-adherence. Clinicians look to clinical practice guidelines as sources of 
best practices for delivering evidence-based health care. It is important to review such 
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guidelines to ensure that the recommendations have been developed using appropriate 
methods and reflect what is known to be effective according to the current research literature. 
 This article reports the results of a systematic review of national and international 
guidelines on the management of patient adherence to medications. This review was conducted 
as part of the „Ascertaining Barriers for Compliance (ABC)‟ Project, an initiative funded by the 
European Union 7th Framework Programme, and followed the PRISMA guidelines for reporting 
systematic reviews [11]. 
Methods 
 To meet this objective, a search strategy was developed to locate and identify clinical 
practice guidelines for medication adherence meeting the following criteria: 
Inclusion/Exclusion criteria: 
1. A publication (e.g., journal article, white paper, consensus document) outlining 
guidelines for addressing medication adherence in clinical practice, health care systems, 
or research. 
2. The guidelines must be national or international in scope (i.e., not center-specific). 
3. The guidelines must deal primarily with medication adherence behavior 
4. The publication‟s purpose must have been to develop guidelines to improve at least one 
component of medication adherence, according to the ABC Taxonomy (i.e., initiation, 
implementation, or persistence) [1]. Only papers that had the development of guidelines 
or recommendations as the primary aim were included. 
5. The publication must have been presented as an official guideline of a 
national/international organization or society with the standing to establish guidelines or 
policy for health care delivery. Expert opinion papers by researchers or clinicians 
working independently that did not have the standing of official guidelines will be 
excluded. 
 The search for guidelines was initiated by identifying and obtaining national and 
international guidelines known to the ABC Project partners.  We then expanded this by sending 
an e-mail request out to all members of the European Society for Persistence, Adherence, and 
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Compliance (ESPACOMP; www.espacomp.eu). Guidelines suggested by these experts were 
obtained to be reviewed for eligibility.  
 A literature search was conducted simultaneously in MEDLINE (PubMed), CINAHL, 
EMBASE, and the Cochrane Library from inception through August 2013 using English-
language search terms. Terms included synonyms for adherence, as the terminology is 
inconsistently used and has changed over time. The PubMed search strategy is shown in Table 
1. The search strings for other databases can be obtained from the authors upon request. 
[Insert Table 1 here] 
 Additionally, internet searches were conducted using applicable search engines to 
identify any possible adherence management guidelines that had not been published in the 
indexed academic literature (i.e. grey literature). We conducted general searches and also 
searches specific to results from specific European countries/regions which were the designated 
focus area for the ABC Project (e.g., .eu [European Union], .uk [United Kingdom], .be [Belgium], 
.fr [France], .de [Germany], .pl [Poland], .ch [Switzerland], .nl [Netherlands], .dk [Denmark], .at 
[Austria], .es [Spain], .it [Italy], .pt [Portugal], .gr [Greece], .hu [Hungary], .cz [Czech Republic], 
.fi [Finland], .hr [Croatia], .ie [Ireland], .is [Iceland], .lu [Luxembourg, .no [Norway], .se 
[Sweden]). We reviewed the first 100 results for general searches and the first 10 results for 
country/region specific searches using combinations of the same search terms used in the 
scientific literature databases. 
 Titles and abstracts of search results for all searches were independently reviewed by 
two reviewers. Final eligibility was determined by reviewing the full text of any reports deemed 
to be potentially eligible on the initial screening. 
 Data extracted from the eligible guidelines included the citation information, year of 
publication, health condition of interest, intended scope of the guideline, how the guideline was 
developed, what specific recommendations were made, and whether the guideline included an 
algorithm for adherence management. Guideline quality was rated using the Global Rating 
Scale of the Appraisal of Guidelines, Research, and Evaluation II (AGREE II-GRS), a five-item 
instrument containing rating the quality of the methods, reporting, presentation, and 
recommendations of guidelines [9]. Each item is scored on a seven-point scale. Quality was 
independently rated by two doctorally-prepared researchers with expertise in medication 
adherence interventions. Reported scores are the average of the reviewers‟ ratings, in 
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accordance with the published methods of the AGREE II-GRS instrument. Disagreements 
between reviewers during data extraction and quality rating were resolved through discussion 
until consensus was reached. 
 Since the guidelines varied greatly in the types of recommendations and the detail 
provided, the lead author conducted a content analysis leading to categories of interventions for 
the purposes of organizing the results. Although taxonomies are being developed to provide 
standardization of types of behavioral interventions, such taxonomies are still under 
development at this time, and the published categories do not include interventions directed at 
health care providers or health systems [12-14]. Thus, we used content analysis guided by 
categories previously used in medication adherence meta-analyses to describe and categorize 
the interventions recommended in the reviewed guidelines. 
Results 
 Experts provided 17 guidelines. The database searches identified 3872 unique citations, 
and our grey literature search yielded an additional five new documents that were subsequently 
screened against inclusion and exclusion criteria (see Figure 1). The most common reason for 
exclusion was that the publication did not provide practice recommendations for improving or 
managing medication adherence. For example, many guidelines provided instructions for which 
medications to prescribe, but did not include any guidance for managing adherence to the 
prescribed medications. Table 2 contains an overview of the 23 guidelines included in this 
review.  
[Insert Figure 1 and Table 2 approximately here] 
 Nine of the 23 guidelines originated from authors or organizations based in the United 
States, three in Canada, three in the United Kingdom (UK), and one each in Australia and 
Spain. Six guidelines had authors from multiple countries in specific regions—one from Central 
and South America, one in the Middle East, one in Europe. Three guidelines were developed by 
authors from a diverse set of nations not focused on any one region. Regarding the intended 
scope of the guidelines, eleven were intended for their country of origin, seven were intended 
for an international audience, and five guidelines did not include specific information about the 
guideline‟s intended scope. The guidelines‟ treatment foci included HIV/AIDS [15-19], 
cardiovascular disease [20-24], contraception [25, 26], menopause [27, 28], mental health [29] 
or depression [30], multiple sclerosis [31], osteoporosis [32], renal transplant [33], and asthma 
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[34]. Three guidelines were general guidelines, and did not specify a health condition focus [35-
38]. Some guidelines included direction for proper prescribing along with how to address 
medication adherence [15]. Others were adherence-focused guidelines that could be used 
along with prescribing guidelines published by the same organization(s) [20]. 
 Table 2 reports a summary of the reported methods used to develop each guideline. 
Although most guidelines used a formal expert consensus panel (n=17), reviewed existing 
literature (n=17), or a combination of both methods (n=13), only seven guidelines provided a 
detailed description of the methods used, including details of the literature search and the 
criteria for consideration, or the procedures for how the expert panel functioned to reach their 
final recommendations. 
 The initial review of included publications extracted a list of 48 types of 
recommendations. This initial list of recommendations was re-reviewed, merging similar 
recommendations under broader themes that emerged as the content of the guideline 
recommendations was reviewed. A summary of strategies suggested by each guideline is 
presented in Table 3. 
[Insert Table 3 approximately here] 
 
Assessment Strategies 
 A majority of the guidelines (n=20; 87%) recommended some type of assessment of 
adherence or of risk factors for non-adherence. Ten studies (43%) recommended that health 
care providers should regularly assess patients‟ adherence to medications. Six of the ten 
suggested self-report measures of adherence as an option, although three of these 
recommended that other measures (e.g. pharmacy refill data, electronic monitoring, clinician 
estimate) should be used as well. Most of the guidelines (n=15; 65%) recommended multiple 
types of assessments (e.g., medication adherence (n=10), readiness to change (n=5), lifestyle 
factors (n=5), patient treatment goals (n=4), barriers to adherence (n=4), side effects or 
persistent symptoms (n=4), literacy (n=3), etc.).  
 Five guidelines recommended assessing a patient‟s readiness to change. This 
assessment permits the provider to gauge the patient‟s level of motivation for enacting changes 
in medication-taking behavior to improve adherence. Adherence management approaches can 
then be tailored to the patient‟s perceived level of readiness to change his or her behavior [37, 
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36, 15]. The Case Management Adherence Guidelines [36] provided examples of tools for 
assessing readiness to change. 
 Recommendations to assess barriers to adherence were found in four guidelines. A 
significant amount of literature addresses potential barriers to effective medication adherence 
[39, 40]. Potential barriers included, but are in no way limited to: medication cost, co-morbidities, 
depression, health beliefs, perceived benefits from the medication, and cognitive function [41, 
39, 42]. 
Educational Strategies 
 Educational strategies are those which recommended that patients or caregivers be 
taught about the patients‟ medications, how to take the medications, or about the health 
condition for which the medication was prescribed. Eighteen of the guidelines (78%) included an 
educational component to their recommendations. Those guidelines that provided detailed 
instructions about educational approaches specified the need to provide clear instructions for 
how patients should take their medications. Three of the guidelines (two focused on 
contraceptives and one general guideline) suggested that health care professionals provide 
instructions to patients for what to do in the case of missed doses. 
 Some guidelines also stated the usefulness of providing additional education for patients 
who may lack the necessary insight into their condition [29, 36]. Providing educational content 
on the consequences of non-adherence and the therapeutic benefits of effective medication 
adherence, it was reasoned, helps the patient to understand the need for adequate adherence, 
providing the necessary knowledge for establishing motivation to adhere. One guideline, dealing 
with adherence in mentally ill patients, recommended cognitive-behavioral therapy and/or 
patient psycho-education to reduce negative perceptions (stigma) regarding medication-taking 
[29]. 
Behavioral Strategies 
 Behavioral strategies involve approaches designed to directly change medication-taking 
behavior or some aspect of the behavior, as opposed to teaching the patient about their 
medication or the reasons for taking medication. Seventeen of the guidelines (74%) included a 
recommendation for a behavioral strategy. The most frequent strategies recommended were 
simplification of the medication regimen (n=10), symptom or side effect monitoring (n=8), and 
providing reminders or medication organizer containers as needed (n=7). Eight guidelines also 
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made nonspecific recommendations for “behavioral strategies” and five recommended 
individually tailoring medication regimens. Behavioral approaches would also include teaching 
patients to associate medication-taking with another habitual behavior. Unfortunately, the lack of 
specificity of the behavioral strategy recommendations in many guidelines made it difficult to 
reach conclusions on which behavioral approaches are actually the most recommended. 
Therapeutic Relationship, Communication, and Health Care Provider Factors 
 The Therapeutic Relationship, Communication, and Health Care Provider Factors 
category includes any recommendations that were focused on changing some aspect of how 
the health care provider should interact with the patient. Nineteen guidelines (83%) made 
recommendations to improve the patient-provider relationship, improve communication between 
patients and providers, or otherwise improve health care providers‟ ability to address patients‟ 
medication needs and concerns. 
 The most common recommendations in this category were to involve the patient in 
treatment decisions (n=9, 47%) and to improve the therapeutic relationship (n=7, 37%). 
Guidelines were generally vague on specific steps providers could take to actually improve 
therapeutic relationship with patients. Particular recommendations that were offered included (in 
addition to including the patient in treatment decisions) improving communication, asking open-
ended questions, being open-minded about patient viewpoints and patients‟ right to autonomy, 
providing rationales for treatment recommendations, and asking patients about their specific 
concerns.  Other less commonly recommended strategies included clinician training to address 
adherence; telephone resources and improved telephone support, particularly after treatment 
initiation; involving other health care disciplines in a multidisciplinary intervention; expanding 
medication management support services for patients with poor adherence; choosing 
medications based on evidence-based guidelines, and creating a medication adherence 
program or having written, updated adherence strategies. 
 Three guidelines recommended motivational interviewing as a method for improving 
adherence to medications [17, 19, 36]. The rationale for these approaches are for the provider 
to develop a rapport with the patient, assess the patient‟s motivation to adhere and readiness to 
change, and then collaborating with the patient to establish goals and make behavioral changes 
necessary to improve medication adherence behavior [36, 29]. The guidelines acknowledged 
that evidence supporting the efficacy of motivational interviewing, cognitive-behavioral therapy, 
and patient psycho-education to improve adherence to medications is inconclusive.  
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Outside Influences and Co-Morbidities 
 The final category involved strategies to address outside influences on adherence and to 
manage co-morbidities. Seven guidelines (70%) recommended engaging or improving family or 
other social support networks. Three (30%) suggested that health care providers should 
address financial barriers to adherence in some manner. Finally, one guideline recommended 
addressing substance abuse in patients with adherence concerns. 
 
Discussion 
 Accepted methods exist for what is considered to be the state of the art for developing 
clinical practice guidelines. These methods include systematically reviewing all available 
evidence and rating the strength of the evidence for each recommendation made [8]. The 
clinical practice guidelines for improving adherence to medications largely did not follow 
recommended guideline development methods. Most adherence guidelines provided limited 
details about the methodologies used to determine their recommendations. Further, the 
recommendations should be subjected to external review, and the procedures for guideline 
development should be published and transparent. Only two of the guidelines in this review 
clearly met these criteria, the International Association of Physicians in AIDS Care [16] and the 
Kidney Disease: Improving Global Outcomes guidelines [33]. Future adherence guideline 
development work should incorporate systematic reviews of existing research, as well as meta-
analytic syntheses of tested interventions to determine the most effective intervention strategies 
for specific patient populations. Guideline developers may also benefit from looking at 
adherence literature from outside their specific clinical focus. 
 Educational approaches have long been at the forefront of interventions necessary to 
improve adherence to medications. The guidelines, however, recognize that education to 
change health behavior works best in conjunction with more active, behavioral approaches, and 
that no approach should rely solely on patient education [43, 44]. Behavioral strategies are an 
important component of intervention programs to manage and improve adherence to 
medications [43-45]. Behavioral strategies vary, but can include unit-dose packaging, 
medication self-monitoring, symptom or side-effect self-monitoring, reminders or other stimuli or 
cues to take medications, feedback, and associating medication-taking with other daily 
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activities. Such approaches help patients to apply knowledge gained from educational 
approaches by actually doing things to modify behavior [43, 44] . 
 A large number of guidelines recommended strategies designed to improve the patient-
provider relationship or to improve communication between patients and providers. This 
demonstrates the importance of implementing strategies that focus not only on patients but also 
on health care providers, in accordance with recent insights from structured literature reviews 
and meta-analyses [46-48]. Patient-provider relationships may also be improved through 
interventions at the health care system, or even health policy level to improve management of 
medication adherence. For example, if policies or systems were changed to facilitate insurance 
reimbursement for behavioral medicine interventions or for patient-provider interactions other 
than face-to-face appointments, providers may be more open to communicating with patients 
about their health and health behavior through methods that patients find more convenient. 
Using such multi-level approaches to adherence improvement is more likely to reach greater 
numbers of patients and yield greater overall improvement than focusing solely on patient-level 
interventions [49, 50]. 
 Fewer than half of the guidelines recommended strategies addressing patients‟ 
motivation to change medication-taking behavior. Motivation is being increasingly recognized as 
a key factor in many types of health behavior changes. Motivation interventions are relatively 
new, compared to many of the intervention approaches for medication adherence. Although 
interventions such as motivational interviewing have been shown to be modestly effective for 
some health behaviors, additional research is needed at this point to further evaluate the 
effectiveness of approaches as part of programs to improve medication adherence [51, 52]. 
What is Missing 
 The guidelines often provided vague strategies, with few specifics. While the particular 
details for implementing adherence management strategies will certainly differ between clinical 
practice locations, guidelines can be more useful if they provide examples of specific 
interventions to assist health care providers in developing the necessary skills and resources to 
better address adherence to medications. For example, Machtinger and Bangsberg [19] provide 
example scripts to use when interviewing patients about their medication regimen and to assess 
patient adherence. The general guideline by Aliotta, Vlasnik, and De Lor [36] provides a number 
of tools to assess factors such as social support, medication knowledge, and readiness to 
change..The use of standardized behavioral change intervention taxonomies, such as that 
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proposed by Michie and colleagues may make it easier to recommend adherence behavior 
change approaches [14]. 
 One piece that was noticeably missing from most guidelines was an algorithm to assist 
health care providers in determining what intervention strategies to use in which situations or to 
address specific modifiable risk factors. While adherence management rarely fits a „recipe‟ 
approach, for health care providers with minimal formal training in addressing adherence issues, 
practice algorithms can be a useful tool until the notice provider reaches a greater level of 
expertise in working with patients to improve and maintain effective medication adherence.  
 Interactive health technology is an emerging area of medication adherence interventions 
[46]. Based on this review, technology interventions are not sufficiently incorporated into 
medication adherence guidelines. Future guidelines should evaluate the efficacy of such 
interventions and include them as potential intervention approaches, if supported by evidence of 
efficacy in the literature. As a whole, the existing guidelines do not sufficiently present the 
evidence base for their recommendations. 
 Dissemination plans for existing guidelines are also lacking. Failure to adequately 
disseminate and promote new guidelines impedes the adoption of useful guidelines into clinical 
practice. Future guidelines should include dissemination plans as part of the development 
process.  
Limitations 
 This review does have some limitations. It is possible that our search strategy missed 
some guidelines, particularly national guidelines published in languages other than English that 
may not have been found in our searches. Our electronic database and web searchers were 
conducted in English, which may have limited our search results. It is also possible that by 
limiting our scope to national and international guidelines, we excluded regional guidelines that 
may have contributed useful information. We attempted to mediate this limitation by conducting 
broad searches and engaging a network of adherence experts in a diverse set of countries 
through the ESPACOMP mailing list. Finally, due to the small number of guidelines per country 
and the differences health condition focus among the guidelines, we decided that comparisons 
between studies would not be appropriate. 
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Conclusion and Recommendations 
 Given the high prevalence and high costs of medication non-adherence, it was 
surprising how few practice guidelines exist for improving and managing patient adherence to 
medications. Many health care organizations establish guidelines for proper prescribing of 
medications for specific health conditions, but do not provide guidelines for addressing how to 
support patients in taking the prescribed medications to ensure the greatest possible health 
benefits from treatment are obtained. It is possible that the groups designing the prescribing 
guidelines do not have members with the background in behavioral medicine and medication 
adherence to facilitate including guidelines for adherence management. 
 The range of recommendations and differences in level of detail make comparing and 
evaluating the guidelines difficult.  Future work in guideline development should be more clearly 
guided by research findings and appropriate synthesis of existing studies. Furthermore, 
comparative effectiveness research methods should then be used to evaluate guidelines to 
ensure that guideline implementation does yield improvements in adherence and health 
outcomes. 
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Table 1: Database Search Terms 
 MEDLINE: 
 Patient compliance [majr] OR treatment refusal [majr] OR "compliance" OR 
adherence OR persistence or concordance OR nonadherence OR non-
adherence OR noncompliance OR non-compliance   
AND 
 practice guideline OR  position paper OR white paper OR policy document OR 
consensus statement OR consensus report OR consensus conference OR 
policy report OR policy guideline OR consensus meeting OR practice 
recommendation OR round table OR roundtable OR task force OR consensus 
guideline 
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 Table 2: List of Included Guidelines 
Primary Author 
Year/ 
Region of 
Origin 
Health 
Population 
Focus 
Guideline 
Scope 
Detailed 
guideline 
methods 
 
Methods 
Quality of 
evidence 
rated?
a
 
Decision 
Algorithm 
Included? 
Mean 
Guideline 
Quality 
Score
b
 
Aliotta [36] 
2004 
USA 
Not specified 
Not 
specified 
N 
Methods not 
described 
N Y 3.0 
International Working 
Group on Enhancing 
Patient Compliance and 
Oral Contraceptive 
Efficacy [26] 
1993 
International 
Contraception International N Literature review N N 2.0 
Canadian Hypertension 
Education Program [24, 
53] 
2006 
Canada 
Hypertension National N 
Expert panel; 
literature review 
Y N 4.5 
Advisory Committee on 
Adherence to the 
Management of High 
Blood Pressure [21] 
1998 
Canada 
Hypertension National N 
Expert panel; 
literature review 
Y N 5.0 
Society of Obstetricians 
and Gynaecologists of 
Canada [25] 
2008 
Canada 
Contraception National Y 
Expert panel; 
literature review 
Y Y 6.5 
American Society of 
Hypertension Writing 
Group [20] 
2010 
USA 
Hypertension National N Literature review N N 3.5 
American Heart 
Association [22] 
1997 
USA 
Cardiovascular 
disease 
National N 
Expert panel; 
literature review 
N N 3.5 
European Society for 
Clinical and Economic 
Aspects of 
Osteoporosis and 
Osteoarthritis (ESCEO); 
International 
Osteoporosis 
Foundation (IOF) [32] 
2013 
Europe 
Osteoporosis International N Literature review N N 4.0 
Kidney Disease: 
Improving Global 
Outcomes (KDIGO) [33] 
2010 
International 
Renal 
transplant 
International Y 
Expert panel; 
literature review 
Y N 6.5 
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Primary Author 
Year/ 
Region of 
Origin 
Health 
Population 
Focus 
Guideline 
Scope 
Detailed 
guideline 
methods 
 
Methods 
Quality of 
evidence 
rated?
a
 
Decision 
Algorithm 
Included? 
Mean 
Guideline 
Quality 
Score
b
 
Grupo de Estudio de 
Sida (GESIDA); 
Sociedad Española de 
Farmacia Hospitalaria 
(SEFH); Plan Nacional 
sobre el Sida (PNS) 
[18] 
2000 
Spain 
HIV/AIDS National 
(Abstract 
only 
available 
for 
review) 
Expert panel Unknown Y 3.5 
Machtinger [19] 
2007 
USA 
HIV/AIDS 
Not 
specified 
N Literature review N N 4.0 
Maia [28] 
2007 
Latin 
America 
Menopause 
(ERT/HRT) 
International Y 
Literature review; 
expert opinion 
survey (n=72) 
N Y 5.0 
National Asthma 
Council [34] 
2005 
Australia 
Asthma National N 
Expert consensus 
workshop; 
literature review 
N N 4.0 
North American 
Menopause Society 
[27] 
1998 
USA 
Menopause 
(ERT/HRT) 
International N 
Expert consensus 
conference 
N N 3.5 
National Collaborating 
Centre for Primary Care 
(NICE) [37] 
2009 
UK 
Not specified National Y 
Literature review; 
expert panel 
N N 6.5 
American College of 
Cardiology [23] 
2002 
USA 
Cardiovascular 
disease 
Not 
specified 
N 
Expert panel 
consensus 
meeting; literature 
review 
N N 4.5 
Panel on Clinical 
Practices for Treatment 
of HIV Infection, U.S. 
Department of Health 
and Human Services 
[15] 
2001 
USA 
HIV/AIDS National N Expert panel N N 5.0 
British HIV Association 
(BHIVA); British 
Association for Sexual 
Health and HIV 
(BASHH) [17] 
2004 
UK 
HIV/AIDS National  N 
Expert panel; 
review of meta-
analyses (2) and 
RCTs (9) 
N N 3.5 
22 
 
 
 
Primary Author 
Year/ 
Region of 
Origin 
Health 
Population 
Focus 
Guideline 
Scope 
Detailed 
guideline 
methods 
 
Methods 
Quality of 
evidence 
rated?
a
 
Decision 
Algorithm 
Included? 
Mean 
Guideline 
Quality 
Score
b
 
Royal Pharmaceutical 
Society [35] 
2013 
UK 
Not specified National  Y 
Expert panel; 
literature review 
N N 4.5 
International 
Association of 
Physicians in AIDS 
Care (IAPAC) [16] 
2012 
International 
HIV/AIDS International Y 
Expert panel; 
literature review 
Y 
Published 
separatel
y 
7.0 
Trivedi [30] 
2007 
USA 
Depression 
Not 
specified 
N 
Methods not 
described 
N N 2.5 
Expert Consensus 
Panel on Adherence 
Problems in Serious 
and Persistent Mental 
Illness [29] 
2009 
USA 
Mental health 
Not 
specified 
Y 
Expert panel 
survey (n=41); 
literature review 
N Y 4.5 
Middle East MS 
Advisory Group [31] 
2010 
Middle East 
Multiple 
Sclerosis 
International N Expert panel N N 4.5 
a
Quality of Evidence Rated refers to whether the guideline authors reported having utilized a rating system for the evidence used to develop the 
practice guideline.  
b
Mean guideline quality score is the mean score of the overall guideline quality assessed by the AGREE II-GRS Instrument [9]. Scores range from 
1 (lowest quality) to 7 (highest quality). 
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Table 3. Intervention Categories by Guideline 
Primary Author 
Health 
Population 
Focus 
Assessment 
Educational 
Approaches 
Behavioral 
Strategies 
Therapeutic 
Relationship/ 
Communication 
Address 
Outside 
Influences & 
Co-
morbidities 
Aliotta [36] Not specified Y Y Y Y Y 
International Working Group on 
Enhancing Patient Compliance and 
Oral Contraceptive Efficacy [26] 
Contraception N Y Y N N 
Canadian Hypertension Education 
Program [24, 53] 
Hypertension Y Y Y Y Y 
Advisory Committee on Adherence 
to the Management of High Blood 
Pressure [21] 
Hypertension Y Y Y N Y 
Society of Obstetricians and 
Gynaecologists of Canada [25] 
Contraception N Y N Y N 
American Society of Hypertension 
Writing Group [20] 
Hypertension Y N Y Y N 
American Heart Association [22] 
Cardiovascular 
disease 
Y Y Y Y N 
ESCEO/IOF [32] Osteoporosis Y Y Y Y N 
KDIGO [33] 
Renal 
transplant 
Y Y N N N 
GESIDA/SEFH/PNS [18] HIV/AIDS Y Y N N N 
Machtinger [19] HIV/AIDS Y N N Y N 
Maia [28] 
Menopause 
(ERT/HRT) 
Y Y Y Y N 
National Asthma Council [34] Asthma Y N Y Y N 
North American Menopause Society 
[27] 
Menopause 
(ERT/HRT) 
N Y Y Y Y 
NICE [37] not specified Y Y Y Y Y 
American College of Cardiology [23] 
Cardiovascular 
disease 
Y Y Y Y N 
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Primary Author 
Health 
Population 
Focus 
Assessment 
Educational 
Approaches 
Behavioral 
Strategies 
Therapeutic 
Relationship/ 
Communication 
Address 
Outside 
Influences & 
Co-
morbidities 
Panel on Clinical Practices for 
Treatment of HIV Infection [15] 
HIV/AIDS Y Y Y Y Y 
BHIVA/BASHH [17] HIV/AIDS Y N Y Y Y 
Royal Pharmaceutical Society [35] Not specified Y N N Y N 
IAPAC [16] HIV/AIDS Y Y Y Y Y 
Trivedi [30] Depression Y Y Y Y Y 
Expert Consensus Panel on 
Adherence Problems in Serious and 
Persistent Mental Illness [29] 
Mental health Y Y Y Y Y 
Middle East MS Advisory Group [31] 
Multiple 
Sclerosis 
Y Y N Y N 
 
 
